Aflibercept injections for persistent wet macular degeneration
Treatments studied
Part of Eyes & vision clinical trials.
This trial studies whether aflibercept injections can help when “wet” age-related macular degeneration is recurring or not fully going away. It focuses on adults who have already had ranibizumab and still have measurable vision in the study eye.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 50 or older
- You have been treated with ranibizumab for wet age-related macular degeneration for up to 1 year
- Your vision in the study eye is at least 20/400 (measured in the clinic)
- You can and agree to come for regular study visits
- You can sign informed consent and follow the study plan
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether certain proteins or molecules in the jelly-like fluid inside the eye can predict why some people with wet age-related macular degeneration do not respond well to standard anti-VEGF injections. By studying these signals, researchers hope to improve future treatment and better tailor care to individual patients.
This study tests a higher dose of a drug called aflibercept, given as eye injections, for people with untreated wet age-related macular degeneration (AMD). The goal is to see if it can improve vision and how often it needs to be given.
This study follows patients receiving aflibercept 8 mg injections in the eye to treat wet age-related macular degeneration (nAMD), a condition that blurs central vision. The goal is to understand how well this treatment works and its safety in routine medical practice.
This study tests a new higher-dose version of an eye injection called aflibercept (Eylea) for people with a specific type of wet age-related macular degeneration called polypoidal choroidal vasculopathy (PCV). The goal is to see if this treatment is effective, long-lasting, and safe, and it may help improve or preserve your vision.
This study looks at how well the higher-dose eye injection aflibercept 8 mg works in people who have already had at least three earlier anti-VEGF injections for wet age-related macular degeneration (wet AMD) or diabetic macular edema (DME). It tests if switching to this stronger dose is safe and effective in real-world care.
This trial tests a new eye injection called AL-001 for people with wet age-related macular degeneration (AMD), a condition that causes blurry vision. The injection aims to stop the growth of abnormal blood vessels in the eye and improve vision.
Hear when a new Age-Related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.